Introduction
============

Intracranial space-occupying neoplasms can be categorized into two main groups: primary tumors and metastatic lesions. Glioma, originating from glial cells, is the most common type, which accounts for almost 80 % of all malignant primary intracranial neoplasms. It has a relatively high incidence of approximately 4-5/100000 population per year, with a peak incidence at the sixth decade of life [@B1], [@B2]. Glioma was classified into 4 histological grades by the World Health Organization (WHO) [@B3]. Grade I and II lesions were considered non-invasive, while grade III and IV correspond to invasive tumors with poor clinical prognosis [@B4]. Current management of glioma consists of surgical excision, radiotherapy and chemotherapyeutic drugs like temozolomide (TMZ), nitrosoureas and bevacizumab [@B5]-[@B7]. Despite the development of above treatment modalities, the outcome of glioma patients still remained unpredictable and unsatisfying. The highest grade glioma, glioblastoma, was reported to have a rapid progression of deterioration, whose median overall survival (OS) was merely 14-16 months after diagnosis [@B8]. Hence, a favorable prognosis of glioma depends on precise diagnosis at early time, effectively individual treatments and valid biomarkers to predict it.

The gold standard diagnosis requires pathological examination. However, biopsy or resection from brain tissue usually cause inevitable lesion. During present clinical practice, noninvasive tools such as computed tomography (CT) and magnetic resonance imaging (MRI) with contrast-enhancing agents were supposed as the first diagnostic procedures for patients with suspected cerebral neoplasms [@B9]. But these two technique measures have limited values in assessment of biological activity, invasion capacity or potential metastatic process of tumors.

Of late, positron emission tomography/ computed tomography (PET/CT), which can potentially address the above-mentioned drawbacks, has gained a lot of attention. It provides additional insight based on functional molecular imaging and features using diverse tracers to visualize biological processes like cell proliferation, membrane biosynthesis, hypoxic metabolism, glucose consumption and expression of amino acid or nucleic acid transporters *in vivo* [@B10]. At present, radiolabeled glucose (^18^F-fluorodeoxyglucose, ^18^F-FDG) and amino acids (^11^C-methionine, ^11^C- MET; ^18^F-fluoroethyltyrosine, ^18^F-FET; 3,4-dihydroxy- 6-^18^F-fluoro-l-phenylalanine, ^18^F-FDOPA and α-^11^C- methyl-tryptophan, AMT) are the most clinically utilized radiopharmaceuticals to detect both primary and recurrent brain tumors [@B11]-[@B15]. Choline analogues (^18^F-fluoromethylcholine, ^18^F-FCho and ^11^C-Choline), thymidine analogues (3′-deoxy-3′-^18^F-fluorothymidine, ^18^F-FLT and 4′-Methyl-^11^C-thiothymidine, ^11^C-4DST) and nitroimidazole derivatives (^18^F-fluoromisonidazole, ^18^F-FMISO, which exclusively trapped in cells with low oxygen concentration and used for hypoxic imaging) also appeared to be successfully novel neuro-oncological PET tracers [@B16]-[@B19].

The potential function of PET/CT scan in oncology is well documented. Besides prognosis of tumor burden, the imaging modality can be even more useful in planning radiation therapy (RT), evaluating treatment-related response and surveilling recurrence or metastasis [@B20]. As popularity of PET/CT technology, increasingly clinical researches were conducted to explore imaging biomarkers capable of predicting survival. Previous studies have already demonstrated some PET-derived quantitative parameters have predictive capability in nasopharyngeal carcinoma, pancreatic carcinoma, lymphoma, non-small cell lung cancer (NSCLC) and some other cancers [@B21]-[@B27]. Given no consensus about the prognostic value of maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV) and the ratio of uptake in tumor to normal (T/N ratio) parameters of PET/CT in glioma patients, we conducted a meta-analysis to assess whether these parameters play positive roles in predicting survival in glioma.

Material and Methods
====================

Literature search
-----------------

We carefully searched PMC, PubMed, EMBASE and WEB of science to collect potentially relevant published articles about the assessment of PET/CT in prognosis of glioma. Medical subheading (Mesh) terms relating to glioma (e.g. "glioma," "glioblastoma" or "brain tumor") in combination with words related to PET (e.g. "PET," "FDG," "FET," "FLT," "MET," "DOPA" or "positron emission tomography") and terms to prognosis (e.g. "prognosis," "survival", "outcome" or "prognostic") were used to retrieve eligible studies for our analyses until September 2018. Furthermore, the references of literatures which may contain additional potentially relevant studies were also examined.

Studies were considered eligible if they met the following criteria: (a) included cancer patients who were pathologically proven glioma; (b) patients who received PET scan tests; (c) investigated the association between the parameters of PET and overall survival (OS) or progression-free survival (PFS); (d) were published as a full paper in English.

Studies were excluded based on the following criteria: (a) patients with brain metastasis due to other sites malignant tumors and non-glioma primary brain tumors; (b) studies which reveal duplicate data or repeated analysis; (c) lack of key information provided by investigators for further analysis; (d) non-human research.

Data extraction
---------------

Main information was evaluated and extracted from included studies by two independent investigators under the guidelines of a critical review checklist of the Dutch Cochrane Centre proposed by Meta-analysis of Observational Studies in Epidemiology (MOOSE) [@B28]. For each selected publication, we recorded the following information: first author, year of publication, country of origin, ethnicity, total number of participants, histological grade, type of PET scan, cut-off value, hazard ratios (HRs) of PET parameters for OS and PFS with their 95% confidence interval (CIs) and P values. In cases where data was not available, we extracted the HR and 95% CIs indirectly by calculating the associated statistical data such as number of events, number at risk, P values of the log-rank test and 95% CIs according to the methods published by Parmar MK et al. [@B29]. For discrepancies at the patient level between the two investigators, we invited another investigator to participate in discussion until consensus achieved in interpretation of results.

Statistical analysis
--------------------

HRs with their 95% CIs obtained from studies were used to calculate combined HRs. Cochran\'s Q test and the Higgins I-squared statistic were applied to investigate the heterogeneity of combined results. If the result of the Q-test revealed P heterogeneity\<0.05 and I²\>50%, suggesting the existence of significant heterogeneity in our analysis, then the random-effect model (DerSimonian-Laird method) was applied to calculate the combined HR [@B30]. Otherwise, a fixed-effect model (the Mantel-Haenszel method) was applied [@B31]. Potential heterogeneity among studies were detected by conducting stratification and meta- regression analyses. Publication bias was detected by performing the Begg\'s funnel plot and Egger\'s linear regression test with a p\<0.05 representing significant [@B32]. The Trim and fill method was used to assess potential asymmetry in the funnel plot. All reported p-values are two-sided. All above calculations were performed on the STATA software, version 16.0 (STATA Corporation, College Station, TX, USA).

Results
=======

Study characteristics
---------------------

The electronic and manual searches output 1732 potentially eligible articles from above databases. After applying the inclusion and exclusion criteria in titles and abstracts, 156 articles remained. Excluding 124 articles without extractable patients\' survival data, a total of 32 articles which reported the prognostic information about PET/CT quantization parameters (SUVmax, MTV or the T/N ratio) in glioma patients were included in our meta-analysis. The study screening procedure and reasons for exclusion are summarized in **Figure [1](#F1){ref-type="fig"}**.

Among 32 articles enrolled in our study, 17 studies dealt with the prognostic value of MTV with 9 [@B33]-[@B41] for OS and 8 [@B34], [@B38]-[@B44] for PFS; 17 studies dealt with the predictive capacity of SUVmax with 10 [@B33], [@B34], [@B45]-[@B51] for OS and 7 [@B34], [@B43], [@B45], [@B49], [@B51], [@B52] for PFS. Only 1 study [@B53] for T/CL (ratio of the tumor to contralateral SUVmax), 1 study [@B54] for G/C (ratio of a glioma to the contralateral cortex), 2 studies [@B51], [@B55] evaluated the diagnostic ability for T/B (ratio of maximal activity to the metabolically active biological tumor volume), 4 [@B36], [@B38], [@B40], [@B41] for TNR (tumor-to- normal region ratio) and 3 [@B34], [@B56], [@B57] for SUVmax/BG (ratio of SUVmax to background activity in the contralateral hemisphere). Considering definitions of these five indicators (T/CL, G/C, T/CL, TNR, SUVmax/BG) had analogous summarization with T/N ratio, we eliminated difference of terminology among studies and combined these parameters as T/N ratio. Thus, 35 studies evaluated T/N ratio with 23 studies [@B34]-[@B38], [@B40], [@B41], [@B45], [@B48], [@B50], [@B51], [@B53]-[@B62] for OS and 12 studies [@B34], [@B38], [@B41]-[@B45], [@B51], [@B55], [@B63], [@B64] for PFS were analyzed in our meta-analysis. Moreover, the eligible articles authored by Takuya Toyonaga [@B40] and Akira Toriihara [@B51] both investigated two different types of PET/CT so that we regarded each article as two studies. In our meta-analysis, different types of PET scanner listed as follows: FDG-PET, ^18^F-FET-PET, ^18^F-DOPA-PET, ^11^C-MET-PET, ^11^C-Choline-PET, FMISO-PET, FLT-PET, AMT-PET and ^62^Cu-ATSM-PET. Thirteen articles enrolled patients with high-grade glioma (grade III-IV). Ethnicity background of patients was classified as Caucasian or Asian and number of patients ranged from 14 to 152. Main characteristics of the 32 articles are described in **Table [1](#T1){ref-type="table"}**.

Predictive value of MTV, SUVmax and T/N ratio for OS
----------------------------------------------------

The combined HR for studies evaluated MTV for OS was 1.14 (95% CI: 0.98-1.32, P heterogeneity\< 0.001). Meanwhile, the prognostic role of SUVmax and T/N ratio was similar with combined HR of 1.69 (95% CI: 1.18-2.41, P heterogeneity\<0.001) and 1.68 (95% CI: 1.40-2.01, P heterogeneity\<0.001, **Figure [2](#F2){ref-type="fig"}**), separately.

Among eligible studies of SUVmax for OS, subgroup analysis was performed in relation to data resource. The results showed that data extracted from univariate analysis had a significant HR of 1.11 (95% CI: 1.01-1.21, P heterogeneity=0.091), while multivariate analysis data had an HR of 2.18 (95% CI: 0.91-5.22, P heterogeneity=0.005).

As for T/N ratio, we conducted subgroup analyses by cut-off value, ethnicity, histological grade, types of PET and data resource. Based on the median cut-off value (1.8), the cohorts were divided into the high value and low value groups. The results indicated that the HRs for T/N ratio were 1.34 (95% CI: 1.12-1.60, P heterogeneity=0.001) and 3.44 (95% CI: 1.94-6.12, P heterogeneity\<0.001) for high and low cut-off value group, respectively. Dealing with different ethnicities, high T/N ratio was a significantly prognostic marker for not only Caucasian patients (HR=1.62, 95% CI: 1.28-2.05, P heterogeneity\<0.001) but also Asian patients (HR=2.25, 95% CI: 1.46-3.47, P heterogeneity=0.007). When performing subgroup analyses stratified by number of participants (since mean number was 56, studies with more than 56 participants were classified as "large" and studies with less than 56 patients were classified as "small"), we found that high T/N ratio predicted unfavorable survival regardless of large (HR=1.33, 95% CI: 1.12-1.58, P heterogeneity\<0.001) or small sample size (HR=2.64, 95% CI: 1.81-3.87, P heterogeneity=0.041). Also, subgroup analyses by PET type revealed that FDG-PET (HR=3.05, 95% CI: 2.10-4.42, P heterogeneity=0.714), ^18^F-FET-PET (HR=1.15, 95% CI: 1.07-1.23, P heterogeneity=0.112) and ^11^C-MET-PET (HR=1.59, 95% CI: 1.36-1.86, P heterogeneity=0.385) could indicate poor OS. Data from univariate (HR=1.21, 95% CI: 1.07-1.36, P heterogeneity =0.389) and multivariate analysis (HR=2.13, 95% CI: 1.62-2.79, P heterogeneity\<0.001) both revealed unfavorable OS. Finally, high T/N ratio was significantly related with lower survival rates in glioma patients with high-grade (III-IV; HR=1.56, 95% CI=1.27-1.92, P heterogeneity=0.001) and other mixed grade (HR= 2.12, 95% CI: 1.42-3.16, P heterogeneity\<0.001). Main results of subgroup analysis are shown in **Table [2](#T2){ref-type="table"}**.

Predictive value of MTV, SUVmax and T/N ratio for PFS
-----------------------------------------------------

For PFS of glioma patients, MTV (HR=1.04, 95% CI: 0.97-1.11, P heterogeneity=0.002) was not a significant indicator. While SUVmax and T/N ratio could act as meaningful predicators for PFS with combined HRs of 1.45 (95% CI: 1.11-1.90, P heterogeneity\<0.001) and 2.07 (95% CI: 1.45-2.95, P heterogeneity\<0.001), respectively. Forest plots of MTV, SUVmax and T/N ratio for PFS are shown in**Figure [3](#F3){ref-type="fig"}**.

Subgroup analysis was carried out by data resource for the meaningful parameter SUVmax and T/N ratio, evaluating that studies adopted univariate analysis had an HR of 1.16 (95% CI: 0.96-1.41, P heterogeneity=0.022) and multivariate analysis showed an HR of 3.15 (95% CI: 1.86-5.35, P heterogeneity=0.134) in terms of SUVmax. As for T/N ratio, it predicted an unfavorable prognosis for PFS regardless of univariate analysis (HR=1.66, 95% CI: 1.14-2.42, P heterogeneity\<0.001) or multivariate analysis (HR=4.30, 95% CI: 2.53-7.33, P heterogeneity =0.991; **Table [2](#T2){ref-type="table"}**).

Heterogeneity, Sensitivity analysis and Publication bias
--------------------------------------------------------

Meta-regression was conducted with the following variables: year of publication, number of participants (large vs. small), ethnicity, histological grade, type of PET/CT, cut-off value and data resource (univariate vs. multivariate) to explore the potential source of heterogeneity among studies. The results showed that year of publication, ethnicity, histological grade, type of PET/CT and data resource did not contribute to the source of heterogeneity. However, number of participants (large vs. small) (P=0.031) and cut-off value (P=0.047) were exception which could explain most of the heterogeneity significantly.

To evaluate sensitivity, we sequentially removed each individual study to investigate their influence on the combined results of SUVmax for OS, SUVmax for PFS, the T/N ratio for OS and the T/N ratio for PFS (**Figure [4](#F4){ref-type="fig"}**). The combined HRs were found to be stable, suggesting no individual study significantly affected the results.

Begg\'s funnel plot and the Egger\'s linear regression test were used to assess publication bias. As shown in **Figure [5](#F5){ref-type="fig"}A**, the funnel plot was asymmetric with the P=0.113. The calculation of Egger\'s test for OS was P\<0.001, revealing existence of bias. For further confirmation, a trim and fill method was conducted and the combined HR with hypothetically non-published studies was recalculated to evaluate the asymmetry (**Figure [5](#F5){ref-type="fig"}B**). However, the recalculated HR of 1.29 (95%CI: 1.07-1.56, P heterogeneity\< 0.001) showed the indicative value of the T/N ratio for OS remained unchanged.

Discussion
==========

PET/CT has developed to be an indispensable imaging technology which was widely used for tumor staging and evaluating clinical outcomes in recent years. Utilizing various radioactive tracers, PET scan was used to delineate areas of tumor based on their increased energy demand in the body, providing real-time information to detect the metabolic behavior of malignant glioma due to abnormal cellular needs [@B65]. Currently, accurate imaging biomarkers could predict response at an early time point after treatment initiation, enabling change or discontinuation of therapy to prevent ineffective treatment or adverse events of treatment [@B66]. Moreover, identification of therapeutic failure may help reduce medical resources and costs. Previous studies have reported that some common PET parameters might act as useful biomarkers for the prediction of OS and PFS in cancer patients. In this article, we performed a comprehensive meta-analysis to summarize the existing evidence of prognostic role of PET/CT in patients with malignant glioma.

In the present study, we analyzed data from 32 articles involving 1715 patients and provided some meaningful findings regarding the use of PET/CT for predicting survival of glioma patients. First, the T/N ratio was associated with poor prognosis for OS and PFS. Subgroup analyses revealed that unfavorable OS and PFS could be found in both univariate and multivariate analysis method regardless of participants number, ethnicity and histological grade of glioma. High or low cut-off value set for T/N ratio did not change the results. Sensitivity analyses and the recalculated HRs via trim and fill method mentioned above further verified our verdict. In terms of SUVmax, the combined data demonstrated its prognostic value for OS and PFS. But the HR of SUVmax evaluating OS by multivariate analysis method and the result evaluating PFS by univariate analysis method revealed to have no statistical significance in subgroup analyses, reducing the persuasive power to some extent. Even so, we should not negate the clinical performance of this parameter in prognostic judgment. Another important index MTV failed to predict outcomes according to our results, nevertheless, we did not allow a definitely negative conclusion on it due to limited research inclusion for the present analyses, thus remaining to be demonstrated in large-scale studies in the future.

The above results emphasized the superior performance of the T/N ratio than SUVmax and MTV in use of PET/CT imaging. Then we retrieved relevant paper trying to explain the consequence. Studies have revealed that the definition regions of interest (ROIs) meant the area of highest contrast agent uptake which showed signal intensity reflected by the morphologic characteristics of lesion [@B60]. SUVmax acted as a semi-quantitative metabolic parameter not only determined by ROI placed in the tumorous area of highest uptake but also recorded for the healthy cerebral cortex [@B67], [@B68]. In fact, radioactivity uptake of normal tissues may vary with each individual, which could lead to the differences in SUV value of tumor tissues with similar biological behavior. However, the index T/N was normalized by calculating the ratio of the tumor SUVmax and the contralateral normal cortex SUVmax, which efficiently excluded the interference of normal tissue in particular. Accordingly, T/N ratio might be more valuable in clinical prognosis when compared to SUVmax. Our analysis results further confirmed this finding. However, MTV (one article in our analysis also defined it as biologic tumor volume (BTV)) [@B42], was a parameter quantitating metabolic volume of tumor burden in contrast to SUVmax and T/N ratio. Recently, Kim YI et al. performed a meta-analysis of ^11^C-MET-PET confirmed that MTV as well as T/N ratio served as important predictors correlated with the eventual outcomes of glioma patients [@B69]. But we could not persist the prognostic value of these indices applicable to all types of PET/CT. After comprehensive analysis, our results of the parameter MTV showed no statistical significance. Based on evidence cited above, we speculated the T/N ratio for predicting clinical outcomes in glioma tended to be more credible than parameter SUVmax and MTV. Considering conflicting data existed in the present research, we expected more systematic evaluation conducted to validate our findings in the future.

Lately, several studies demonstrated that these metabolic and volumetric parameters were closely associated with the eventual outcomes of patients with glioma [@B69], [@B70]. Conducting the research work near-simultaneously, our research might provide more reliable results than these previous analyses because it contained a larger number of studies selected through strict inclusion criteria. In addition, we expanded the findings of previous narrative reviews by investigating different PET tracers and providing a quantitative overview of the prognostic accuracy of those PET scans. So far, the value of some tracers, such as radiolabeled glucose FDG and amino acid PET tracers ^11^C-MET as well as ^18^F-FET, has been evaluated with promising results in glioma patients in terms of tumor delineation, prognostication and the differentiation of tumor recurrence after adjuvant chemoradiotherapy. While novel promising glioma PET tracers like ^18^F-FLT and AMT are under investigation. In our research of T/N ratio for OS, including 7 studies for FDG-PET, 6 studies for ^18^F-FET-PET and 4 studies for ^11^C-MET-PET, whereas other 6 types of PET were all mentioned in each 1 study separately. After systematic analyses, we demonstrated that FDG-PET, ^18^F-FET-PET and ^11^C-MET-PET were closely correlated with poor OS, but could not validate the indicative capability of the remaining 6 PET types due to limited evidence. Remarkably, Vincent Dunet et al. once conducted a meta-analysis confirmed that even though both FDG-PET and ^18^F-FET-PET quantitative parameters allowed distinction between low and high-grade glioma, only T/N ratio on ^18^FET-PET has predictive capacity for the diagnosis of brain tumor and nontumorous lesions, but not FDG-PET [@B71]. Compared with our study outcomes, it showed inconsistent results in conclusion. That should be mentioned, we still need more convictive studies regarding comparisons between these two types of PET/CT or even among other different PET tracers in clinical trials for glioma.

Univariate meta-regression was carried out to explore the potential source of heterogeneity, indicating number of participants and cut off value could explain most of the heterogeneity among studies evaluating T/N ratio for OS. However, these types of heterogeneity were difficult to exclude since cut-off value was set by each researcher as recruitment of the same numeric value seemed difficult to enforce. Yet, we have attempted to accommodate various inclusion criteria to minimize differences among study populations, but some unreported or unmeasured patient characteristics, in part, prevented us from controlling the impact of heterogeneity from participants. These required studies including more participants from different backgrounds to explore the prognostic value of the T/N ratio. Meanwhile, publication bias was found in the meta-analysis and the recalculated HR by the trim and fill method showed statistical significance of the T/N ratio for OS which reconfirmed the prognostic role of high T/N ratio for patients\' outcomes.

Several shortcomings in our analysis should be considered. First, the studies retrieved were limited in articles published in English, which might partially contribute to publication bias although the result did not change after recalculating by trim and fill method. Second, this research only included 1715 patients which might reduce the persuasive power of the results to some extent. Third, the clinical treatments are inevitable factors affecting the test results, since patients usually received different therapies (e.g. various chemotherapy schemes, the types of surgery or radiotherapy). Last but not the least, many included studies did not provide direct sufficient HRs so that we had to extrapolat from the survival curves which might result in certain inaccuracy.

Conclusion
==========

The results of this meta-analysis confirmed that PET/CT parameter T/N ratio tended to be superior to SUVmax and MTV in predicting outcomes among glioma patients. Despite the publication bias observed across studies, the parameter could still provide useful information for survival time of patients with glioma and progression of the disease. Due to limited number of included trials in our analysis, future large-scale studies are necessary to validate our findings and explore more helpful prognostic variables associated with PET/CT images to enhance survival rate of glioma patients.
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###### 

Main characteristics of the studies included in this meta-analysis.

  Author                   Year   Country       Number   Grade    Types                     Ethnicity   Cut-off value                     
  ------------------------ ------ ------------- -------- -------- ------------------------- ----------- --------------- ----------------- -----------------
  Ce´cile Colavolpe        2011   France        41       III-IV   FDG-PET                   Caucasian   NR              NR                1.2
  Albert J.S. Idema        2012   Netherlands   26       III-IV   FLT-PET                   Caucasian   NR              NR                NR
  Ce´cile Colavolpe        2012   France        25       III-IV   FDG-PET                   Caucasian   NR              7                 1.348
  Sellam Karunanithi       2013   India         33       I-IV     ^18^F-FDOPA-PET           Asian       NR              NR                1.51
  Nathalie L. Jansen       2013   Germany       59       II       ^18^F-FET-PET             Caucasian   NR              NR                NR
  Reinhart Sweeney         2013   Germany       28       II-IV    ^18^F-FET-PET             Caucasian   NR              2.6               NR
  Niklas Thon              2014   Germany       98       II-IV    ^18^F-FET-PET             Caucasian   NR              2.3               NR
  Wanhu Li                 2014   China         16       III-IV   ^11^C-Choline-PET         Asian       NR              0.995             1.42
  David O. Kamson          2014   USA           39       III-IV   AMT-PET                   Caucasian   NR              4.62              NR
  Johannes Schwarzenberg   2014   USA           30       III-IV   ^18^F-FDOPA-PET           Caucasian   18              NR                NR
  Nathalie L. Jansen       2014   Germany       121      III-IV   ^18^F-FET-PET             Caucasian   NR              NR                1.8
  Fen Zhao                 2014   China         56       III-IV   ^18^F-FET-PET             Asian       NR              NR                10.94
  Jens Gempt               2015   Germany       152      II-IV    ^18^F-FET-PET             Caucasian   NR              NR                1.6/3
  Min Young Yoo            2015   Korea         30       III-IV   ^11^C-MET-PET             Asian       35              NR                3.3
  Kentaro Kobayashi        2015   Japan         33       II-IV    ^11^C-MET-PET             Asian       59.95           NR                3.42
  Thomas Pyka              2015   Germany       113      III-IV   ^18^F-FET-PET             Caucasian   19.7            NR                2.74
  Carlos Leiva-Salinas     2016   USA           56       IV       FDG-PET                   Caucasian   NR              NR                2
  Takuya Toyonaga          2016   Japan         32       IV       FMISO-PET/FDG-PET         Asian       15.01/15.01     NR                4.19/1.42
  Gloria C. Chiang         2016   USA           44       IV       FDG-PET                   Caucasian   NR              NR                NR
  Katsuya Mitamura         2016   Japan         36       II-IV    FLT-PET                   Asian       NR              NR                NR
  Soren Moller             2016   Denmark       31       III-IV   ^18^F-FET-PET             Caucasian   NR              NR                NR
  Tae-Young Jung           2016   Korea         35       III-IV   ^11^C-MET-PET             Asian       60              NR                2.8
  Takano K                 2016   Japan         35       II-III   ^11^C-MET-PET             Asian       NR              NR                2
  Nina Poetsch             2017   Austria       142      II-IV    ^11^C-MET-PET             Caucasian   NR              NR                2.4
  Egesta Lopci             2017   Italy         109      I-IV     ^11^C-MET-PET             Caucasian   NR              3.5               NR
  Giovanni Morana          2017   Italy         18       II-IV    ^18^F-DOPA-PET            Caucasian   NR              NR                1.53
  Comron Hassanzadeh       2017   USA           30       IV       FDG-PET                   Caucasian   NR              NR                1.5
  Charlotte Debus          2018   Germany       14       IV       ^18^F-FET-PET             Caucasian   NR              NR                2.92
  Dongwoo Kim              2018   Korea         59       II-IV    FDG-PET                   Asian       NR              NR                0.8
  Soyoung Kim              2018   Korea         73       II-IV    ^11^C-MET-PET             Asian       1.0             NR                1.6
  Chirag B. Patel          2018   USA           45       I-IV     ^18^F-DOPA-PET            Caucasian   NR              NR                1.7
  Akira Toriihara          2018   Japan         56       II-IV    ^62^Cu-ATSM-PET/FDG-PET   Asian       NR              1.3/1.5/4.1/6.8   1.6/1.8/2.0/2.1

MTV: metabolic tumor volume; SUVmax: maximum standardized uptake value; T/N ratio: ratio of uptake in tumor to normal; NR: not reported.

###### 

Meta-analysis results.

  Outcome   Parameters   Variables       Study Number   Model    HR (95%CI)             P heterogeneity
  --------- ------------ --------------- -------------- -------- ---------------------- -----------------
  OS        MTV          All             9              Random   1.14 (0.98,1.32)       \<0.001
            SUV max      All             10             Random   **1.69 (1.18,2.41)**   \<0.001
                         Resource                                                       
                         Univariate      4              Fixed    **1.11 (1.01,1.21)**   0.091
                         Multivariate    6              Random   2.18 (0.91,5.22)       0.005
            T/N ratio    All             23             Random   **1.68 (1.40,2.01)**   \<0.001
                         Cut-off value                                                  
                         Low             11             Random   **3.44 (1.94,6.12)**   \<0.001
                         High            10             Random   **1.34 (1.12,1.60)**   0.001
                         Ethnicity                                                      
                         Caucasian       11             Random   **1.62 (1.28,2.05)**   \<0.001
                         Asian           12             Random   **2.25 (1.46,3.47)**   0.007
                         Grade                                                          
                         High            13             Random   **1.56 (1.27,1.92)**   0.001
                         Mixed           10             Random   **2.12 (1.42,3.16)**   \<0.001
                         Resource                                                       
                         Univariate      8              Fixed    **1.21 (1.07,1.36)**   0.389
                         Multivariate    15             Random   **2.13 (1.62,2.79)**   \<0.001
                         Number                                                         
                         Small           13             Random   **2.64 (1.81,3.87)**   0.041
                         Large           10             Random   **1.33 (1.12,1.58)**   \<0.001
                         Type of PET                                                    
                         FDG-PET         7              Fixed    **3.05 (2.10,4.42)**   0.714
                         ^18^F-FET-PET   6              Fixed    **1.15 (1.07,1.23)**   0.112
                         ^11^C-MET-PET   4              Fixed    **1.59 (1.36,1.86)**   0.385
  PFS       MTV          All             8              Random   1.04 (0.97,1.11)       0.002
            SUV max      All             7              Random   **1.45 (1.11,1.90)**   \<0.001
                         Resource                                                       
                         Univariate      4              Random   1.16 (0.96,1.41)       0.022
                         Multivariate    3              Fixed    **3.15 (1.86,5.35)**   0.134
            T/N ratio    All             12             Random   **2.07 (1.45,2.95)**   \<0.001
                         Resource                                                       
                         Univariate      8              Random   **1.66 (1.14,2.42)**   \<0.001
                         Multivariate    4              Fixed    **4.30 (2.53,7.33)**   0.991

Bold: with statistical significance; HR: hazard ratio; MTV: metabolic tumor volume; SUVmax: maximal standard uptake value; T/N ratio: ratio of uptake in tumor to normal; OS: overall survival; PFS: progression-free survival.
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